GOCO INVESTOR DEADLINE FRIDAY: Hagens Berman, National Trial Attorneys, Alerts GoHealth (GOCO) Investors to November 20th Lead Plaintiff Deadline, Encourages Investors with Losses to Contact the Firm

SAN FRANCISCO, Nov. 16, 2020 (GLOBE NEWSWIRE) — Hagens Berman urges GoHealth, Inc. (NASDAQ: GOCO) investors to contact the firm now. A securities class action related to GoHealth’s initial public offering has been filed and GOCO investors may have sufficient losses to move for lead plaintiff.

Class
Period: July 12, 2020 – Sept. 21, 2020
Lead Plaintiff Deadline: Nov. 20, 2020
Visit
:
www.hbsslaw.com/investor-fraud/GOCO
Contact An Attorney Now
:
[email protected] 
  844-916

0895

GoHealth
(
GOCO
)
Securities Class Action:

The complaint alleges that GoHealth’s IPO offering documents contained materially false and misleading statements and omissions. Specifically, the offering documents allegedly misrepresented or failed to disclose that: (1) the Medicare insurance industry was undergoing a period of elevated customer churn that began in the first half of 2020; (2) GoHealth’s unique business model and its limited carrier base exposed the company to a higher risk of churn; (3) GoHealth suffered from degradations in customer retention as a result of elevated churn; (4) GoHealth had already entered into materially less favorable revenue sharing arrangements with its external sales agents; and, (5) GoHealth internally projected these adverse trends would continue and worsen after its IPO.

The IPO offering documents allowed GoHealth to go public, issuing 43.5 million shares to investors at $21 per share for total proceeds of about $913.5 million.

However, since the IPO, GoHealth has reported disappointing financial performance resulting from the material facts omitted in the IPO offering documents and its common stock has suffered significant price declines. By Sept. 15, 2020, GoHealth Class A common stock closed at just $12.53 per share, or over 40% below the $21 per share price investors paid for the stock in the IPO less than two months previously.

“We’re focused on investors’ losses and proving GoHealth’s IPO offering documents misrepresented or omitted churn data when going public,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are a GoHealth investor or may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding GoHealth should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 8449160895 or email [email protected].


About Hagens Berman


Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation.   More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact
:

Reed Kathrein, 844-916-0895



Co-Diagnostics, Inc. Announces Q3 2020 Financial Results Including YTD Net Income per Common Share of $1.07

Company also announces receipt of CE markings for both Logix Smart ABC and SARS-CoV-2 2-gene tests

PR Newswire

SALT LAKE CITY, Nov. 16, 2020 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the third quarter ended September 30, 2020 and provided updates on Company developments, including receipt of CE markings for both the recently developed Logix Smart ABC (Influenza A/B, SARS-CoV-2) test kit for simultaneous detection of Influenza A, Influenza B, and SARS-CoV-2 and Logix Smart SARS-CoV-2 (genes RdRp/E) multiplex test kit for detection of SARS-CoV-2, the virus that causes COVID-19.


Q3 2020 Highlights:

  • Company continues COVID-19 test sales and reports $21.8 million of revenue in Q3;
  • Quarterly net income of $15.7 million and net income per diluted common share of $0.53;
  • Year-to-date net income of $29.7 million and $1.07 per diluted common share;
  • Additionally, CoSara Diagnostics, the Company’s India joint venture, also continues COVID-19 sales and reports $3.0 million of revenue in Q3, nearly a 3-fold increase over Q2;
  • Quarterly net gain from investment in CoSara increased to $748,000 from $250,000 in Q2;
  • Stockholders’ equity increased to $52.7 million compared to $1.7 million at the beginning of the year.
  • Continues to show strong gross margins of 73% on quarterly sales;
  • Cash, cash equivalents and marketable securities were $27.3 million as of September 30, 2020, an increase of $26.4 million over 12/31/2019.


Q4 2020 Mid-Quarter Highlights:

  • Company completes design work and verification for influenza A, influenza B, and COVID-19 (“ABC”) multiplex panel and began distributing on a Research Use Only basis to laboratories in the first week of October;
  • CE markings received for both Co-Diagnostics “ABC” and SARS-CoV-2 2-gene tests; both tests are designed for use in saliva and other respiratory tract samples like nasal swabs, and sputum;
  • Indian CDSCO approval for SARS-CoV-2 2-gene multiplex test expected to be granted soon;
  • Company announced that its partner Clinical Reference Lab has begun selling its CRL Rapid Response™ COVID-19 test directly to consumers, which uses a simple saliva collection device that can be self-administered at home, work or any other setting. The test uses CoPrimer™ probes and primers developed by Co-Diagnostics with high degrees of sensitivity and specificity;
  • Company receives increased patent protection from the United States Patent and Trademark Office for the novel CoPrimer™ technology used in the Company’s molecular diagnostic tests;
  • Company demonstrates that the CoPrimer platform technology can be used to identify the presence of SARS-CoV-2 in human saliva samples without first requiring costly and time-consuming RNA extraction, and plans development projects to incorporate extraction-free products in upcoming offerings.

“Co-Diagnostics continues to see widespread uptake of our COVID-19 test domestically and abroad, and we believe our customer and distributor bases are laying the foundation for a strong future,” said Dwight Egan, Chief Executive Officer. “Development projects both completed and ongoing have helped position Co-Diagnostics as a key player in the battle against the coronavirus pandemic, including receipt today of two important CE markings that will allow our ABC and COVID-19 2-gene tests to be sold as in vitro diagnostics in areas that accept CE markings as valid regulatory approval. The strength and flexibility of our technology platform as illustrated by our enhanced patent protection and successful proof of concept in extraction-free COVID-19 tests underscore our core competency as a forward-looking technology company with a expanding menu of critical diagnostic tools.”

The Company will host an earnings call at 4:30 pm EDT today. Participants can register for access to the webcast here. The call will be recorded and later made available on the Company’s website.

About Emergency Use Authorization:
The Co-Diagnostics SARS-CoV-2 Test has been made available under an emergency access mechanism called an Emergency Use Authorization (EUA). The EUA is supported by the Secretary of Health and Human Service’s (HHS’s) declaration that circumstances exist to justify the use of in vitro diagnostics (IVDs) under EUA for the detection and/or diagnosis of COVID-19. An IVD made available under an EUA has not undergone the same type of review as an FDA cleared IVD. However, based on the totality of scientific evidence available, it is reasonable to believe that this IVD may be effective in the detection of COVID-19. The EUAs for these tests are in effect for the duration of the COVID-19 emergency, unless terminated or revoked (after which the tests may no longer be used). An FDA cleared IVD should be used instead of an IVD under EUA, when applicable and available.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.

Forward-Looking Statements:

This press release contains forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.  Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.  Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.


CO – DIAGNOSTICS, INC.


CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)


September 30,
2020


December 31,
2019


Assets

Current assets

Cash and cash equivalents

$

21,230,362

$

893,138

Marketable investment securities

6,050,000

Accounts receivable, net

10,640,417

131,382

Inventory

10,726,982

197,168

Prepaid expenses

384,642

362,566

Deferred tax asset

2,914,781

Total current assets

51,947,184

1,584,254

Property and equipment, net

538,279

196,832

Investment in joint venture

2,165,037

434,240

Total assets

$

54,650,500

$

2,215,326


Liabilities and stockholders’ equity

Current liabilities

Accounts payable

$

250,465

$

5,959

Accrued expenses

786,063

200,788

Accrued expenses (related party)

120,000

120,000

Deferred revenue

657,925

1,323

Total current liabilities

1,814,453

328,070

Accrued expenses-long-term (related party)

60,000

150,000

Total liabilities

1,874,453

478,070


Commitments and contingencies (Note 8)


Stockholders’ equity

Convertible preferred stock, $0.001 par value; 5,000,000 shares
authorized; 0 and 25,600 shares issued and outstanding as of
September 30, 2020 and December 31, 2019, respectively

26

Common Stock, $0.001 par value; 100,000,000 shares authorized;
28,161,259 and 17,342,922 shares issued and outstanding as of
September 30, 2020 and December 31, 2019, respectively

28,161

17,343

Additional paid-in capital

48,044,352

26,687,701

Accumulated earnings (deficit)

4,703,534

(24,967,814)

Total stockholders’ equity

52,776,047

1,737,256

Total liabilities and stockholders’ equity

$

54,650,500

$

2,215,326

 

 


CO – DIAGNOSTICS, INC.


CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


(Unaudited)


Three Months Ended
September 30, 2020


Nine Months Ended
September 30, 2020


2020


2019


2020


2019

Revenue

$

21,818,753

$

41,434

$

47,407,555

$

106,408

Cost of revenue

5,821,281

20,365

12,278,326

59,626

Gross profit

15,997,472

21,069

35,129,229

46,782

Operating expenses

Sales and marketing

798,474

262,360

1,457,148

770,539

Administrative and general

2,203,417

1,060,763

5,853,935

2,508,895

Research and development

921,889

331,027

2,072,160

990,923

Depreciation and
amortization

35,490

17,006

81,456

46,768

Total operating expenses

3,959,270

1,671,156

9,464,699

4,317,125

Income (loss) from
operations

12,038,202

(1,650,087)

25,664,530

(4,270,343)

Other income (expense)

Interest income

29,992

12,207

75,740

32,255

Interest expense

(10)

(106,437)

Gain on disposition of assets

850

Gain (loss) on equity method
investment in joint venture

748,557

(109,876)

1,016,297

(116,876)

Total other income
(expense)

778,549

(97,679)

1,092,037

(190,208)

Income (loss) before income
taxes

12,816,751

(1,747,766)

26,756,567

(4,460,551)

Income tax provision (benefit)

(2,914,781)

(2,914,781)

Net income (loss)

$

15,731,532

$

(1,747,766)

$

29,671,348

$

(4,460,551)

Earnings (loss) per common
share:

Basic

$

0.56

$

(0.10)

$

1.13

$

(0.27)

Diluted

$

0.53

$

(0.10)

$

1.07

$

(0.27)

Weighted average shares
outstanding:

Basic

28,084,267

17,328,787

26,172,439

16,809,085

Diluted

29,597,792

17,328,787

27,621,531

16,809,085

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/co-diagnostics-inc-announces-q3-2020-financial-results-including-ytd-net-income-per-common-share-of-1-07–301174011.html

SOURCE Co-Diagnostics

mdf commerce Announces that its Chief Financial Officer Will Depart the Company at the End of the Year


A succession plan


is


in place

MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) — mdf commerce inc. (TSX:MDF), a leader in SaaS commerce technology solutions, announces that Paul Bourque, Chief Financial Officer, will leave the Company at the end of the year.

Deborah Dumoulin, previously a partner at PwC Canada and more recently Vice-President Finance and Financial Reporting of Fiera Capital Corporation, is presently acting as a strategic advisor to mdf commerce. Having extensive financial management and operational experience, Deborah will work with Paul during a transition period and assume the role of CFO in January.

“Paul’s contribution to the Company has been invaluable,” said Luc Filiatreault, President and CEO of mdf commerce. “His work has allowed the Company to grow effectively over the years and has brought us to a position of financial strength that will allow us to execute our Strategic Plan. He will remain with us until the end of December to facilitate a smooth transition. Deborah’s extensive international experience will be of great value as we continue to accelerate our growth plans.”

About
mdf
commerce
inc.

mdf
commerce inc. (TSX:MDF), formerly known as Mediagrif Interactive Technologies Inc., enables the flow of commerce by providing a broad set of SaaS solutions that optimize and accelerate commercial interactions between buyers and sellers. Our platforms and services empower businesses around the world, allowing them to generate billions of dollars in transactions on an annual basis. Our strategic sourcing, unified commerce and emarketplace platforms are supported by a strong and dedicated team of more than 600 employees based in Canada, the United States, Denmark, Ukraine and China. For more information, please visit us at mdfcommerce.com, follow us on LinkedIn or call at 1-877-677-9088.

This press release contains certain forward-looking statements with respect to the Corporation. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those expected by these forward-looking statements. We consider the assumptions on which these forward-looking statements are based to be reasonable but caution the reader that these assumptions regarding future events, many of which are beyond our control, may ultimately prove to be incorrect since they are subject to the risks and uncertainties that affect us. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities legislation. Unless otherwise indicated, all amounts are in Canadian dollars.

For further
information:

mdf
commerce

André Leblanc
Vice President, Marketing and Public Affairs
Phone: +1 (514) 961-0882
Email: [email protected]



HealthEquity Sets Date to Announce Third Quarter Results

DRAPER, Utah, Nov. 16, 2020 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the largest independent HSA custodian, today announced plans to release its third quarter fiscal year 2021 financial results following the close of regular stock market trading hours on Monday, December 7, 2020. Following the news release, HealthEquity management plans to host a conference call for investors on Monday, December 7, 2020, at 4:30 p.m. ET during which management will review highlights from the Company’s third quarter results.

HealthEquity’s
Third
Quarter Fiscal
Year
20
2
1
Conference Call
Date: December 7, 2020
Time: 4:30 pm Eastern Time / 2:30 pm Mountain Time
Dial-In: 1-844-791-6252 (US and Canada)
  1-661-378-9636 (International)
Conference ID:  4225999
Webcast: ir.healthequity.com 

About HealthEquity

HealthEquity administers Health Savings Accounts (HSAs) and other consumer-directed benefits for our more than 12 million accounts in partnership with employers, benefits advisors, and health and retirement plan providers who share our mission to connect health and wealth and value our culture of remarkable “Purple” service. For more information, visit www.healthequity.com.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding our industry, business strategy, plans, goals and expectations concerning our markets and market position, product expansion, future operations, expenses and other results of operations, revenue, margins, profitability, future efficiencies, tax rates, capital expenditures, liquidity and capital resources and other financial and operating information. When used in this discussion, the words “may,” “believes,” “intends,” “seeks,” “anticipates,” “plans,” “estimates,” “expects,” “should,” “assumes,” “continues,” “could,” “will,” “future” and the negative of these or similar terms and phrases are intended to identify forward-looking statements in this press release.

Forward-looking statements reflect our current expectations regarding future events, results or outcomes. These expectations may or may not be realized. Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give you no assurance these expectations will prove to be correct. Some of these expectations may be based upon assumptions, data or judgments that prove to be incorrect. Actual events, results and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties and other factors. Although it is not possible to identify all of these risks and factors, they include, among others, risks related to the following:

  • the impact of the COVID-19 pandemic on the Company, its operations and its financial results;
  • our ability to realize the anticipated financial and other benefits from combining the operations of WageWorks with our business in an efficient and effective manner;
  • our ability to compete effectively in a rapidly evolving healthcare and benefits administration industry;
  • our dependence on the continued availability and benefits of tax-advantaged health savings accounts and other consumer-directed benefits;
  • our ability to successfully identify, acquire and integrate additional portfolio purchases or acquisition targets;
  • the significant competition we face and may face in the future, including from those with greater resources than us;
  • our reliance on the availability and performance of our technology and communications systems;
  • recent and potential future cybersecurity breaches of our technology and communications systems and other data interruptions, including resulting costs and liabilities, reputational damage and loss of business;
  • the current uncertain healthcare environment, including changes in healthcare programs and expenditures and related regulations;
  • our ability to comply with current and future privacy, healthcare, tax, investment advisor and other laws applicable to our business;
  • our reliance on partners and third-party vendors for distribution and important services;
  • our ability to develop and implement updated features for our technology and communications systems and successfully manage our growth;
  • our ability to protect our brand and other intellectual property rights; and
  • our reliance on our management team and key team members.

For a detailed discussion of these and other risk factors, please refer to the risks detailed in our filings with the Securities and Exchange Commission, including, without limitation, our most recent Annual Report on Form 10-K and subsequent periodic and current reports. Past performance is not necessarily indicative of future results. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor Relations Contact:

Richard Putnam
801-727-1209
[email protected]



Stag Industrial Announces Public Offering Of Common Stock

PR Newswire

BOSTON, Nov. 16, 2020 /PRNewswire/ — STAG Industrial, Inc. (the “Company”) (NYSE:STAG) today announced the commencement of an underwritten public offering of an aggregate of 8,000,000 shares of its common stock on a forward basis in connection with the forward sale agreement described below.  The forward purchaser (or its affiliate) and the Company intend to grant the underwriters of the offering a 30-day option to purchase up to an additional 1,200,000 shares of common stock.

The Company intends to use the net proceeds it receives from the offering, if any, to fund acquisitions, to repay indebtedness outstanding under its unsecured credit facility (which was incurred to fund acquisitions and for working capital purposes), for working capital and other general corporate purposes, or a combination of the foregoing.

Citigroup, Jefferies and Raymond James will serve as the joint book-running managers for the offering.

In connection with the offering of shares of its common stock, the Company expects to enter into a forward sale agreement with Citigroup Global Markets Inc. (or its affiliate), referred to in its capacity as the forward purchaser.  In connection with such forward sale agreement, the forward purchaser (or its affiliate) is expected to borrow from third parties and sell to the underwriters 8,000,000 shares of the Company’s common stock (or 9,200,000 shares if the underwriters’ option is exercised in full and the Company elects to execute an additional forward sale agreement).

Pursuant to the terms of the forward sale agreement, and subject to its right to elect cash or net share settlement, the Company is obligated to issue and deliver, upon physical settlement of such forward sale agreement on one or more dates specified by the Company occurring no later than November 16, 2021 the number of shares of the Company’s common stock underlying the forward sale agreement in exchange for a cash payment per share equal to the forward sale price under the forward sale agreement.  The Company expects to physically settle the forward sale agreement and receive proceeds, subject to certain adjustments, from the sale of its shares of common stock upon one or more such physical settlements within approximately one year from the date of the prospectus supplement relating to the offering.

A registration statement relating to these securities became effective upon filing with the Securities and Exchange Commission.  This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

The offering of these securities will be made only by means of a preliminary prospectus supplement and related base prospectus.  Copies of the preliminary prospectus supplement, final prospectus supplement (when available) and the related base prospectus may be obtained from: (a) Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146 or by e-mailing [email protected]; (b) Jefferies, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388 or by e-mailing [email protected]; (c) Raymond James, Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716, by telephone at (800) 248-8863 or by e-mailing [email protected]; or (d) the Securities and Exchange Commission’s website at http://www.sec.gov.

About STAG Industrial, Inc.

STAG Industrial, Inc. is a real estate investment trust focused on the acquisition, ownership and operation of single-tenant, industrial properties throughout the United States.  As of September 30, 2020, the Company’s portfolio consisted of 462 buildings in 38 states totaling approximately 92.3 million rentable square feet.

Forward-Looking Statements

This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions.  Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, are generally identifiable by use of the words “believe,” “will,” “expect,” “intend,” “anticipate,” “estimate,” “should,” “project” or similar expressions.  Forward-looking statements in this press release include, among others, statements about the terms and size of the offering, the timing and manner of any forward settlement and the use of proceeds from the offering.  You should not rely on forward-looking statements since they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company’s control and which could materially affect actual results, performances or achievements.  Factors that may cause actual results to differ materially from current expectations include, but are not limited to, the risk factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, as updated by the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, each filed with the Securities and Exchange Commission.  Accordingly, there is no assurance that the Company’s expectations will be realized. Except as otherwise required by the federal securities laws, the Company disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/stag-industrial-announces-public-offering-of-common-stock-301174008.html

SOURCE STAG Industrial, Inc.

BioHiTech Global Reschedules Third Quarter 2020 Financial Results and Corporate Update to Thursday, November 19, 2020

Conference call now to be held Thursday, November 19, at 4:30 p.m. Eastern Time

PR Newswire

CHESTNUT RIDGE, N.Y., Nov. 16, 2020 /PRNewswire/ — BioHiTech Global, Inc. (“BioHiTech” or the “Company”) (NASDAQ: BHTG), a sustainable technology and services company, announces today that it will report third quarter 2020 financial results on Thursday, November 19, 2020 after the market close.

Management will host a conference call at 4:30 p.m. ET on Thursday, November 19, 2020 to review financial results and provide an update on corporate developments.  Following management’s formal remarks, there will be a question and answer session.

Participants are asked to pre-register for the call via the following link:
https://dpregister.com/sreg/10150010/dd340fff34

Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay.  Those without Internet access or who are unable to pre-register may dial in by calling 1-866-652-5200 (domestic) or 1-412-317-6060 (international).  All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioHiTech Global call.

The conference call will be available through a live webcast found here:
https://services.choruscall.com/links/bhtg201116.html

It will also be broadcast live through the Company’s website with the following link:
http://investors.biohitechglobal.com/events-and-webcasts

A webcast replay of the call will be available approximately one hour after the end of the call through February 19, 2021.  The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 10150010. A telephonic replay of the call will be available through December 4, 2020.

About BioHiTech Global
BioHiTech Global, Inc. (NASDAQ: BHTG), is a technology services company focused on providing cost-effective solutions that improve environmental outcomes. Our technologies for waste management include the patented processing of municipal solid waste into a valuable renewable fuel, biological disposal of food waste on-site, and proprietary real-time data analytics tools to reduce food waste generation. When used individually or in combination, our solutions lower the carbon footprint associated with waste transportation and can reduce or virtually eliminate landfill usage. In addition, we distribute a patented technology that achieves high-level disinfection of spaces such as classrooms, hotel or hospital rooms and other enclosed areas to combat the spread of viruses and bacteria without the use of harsh chemicals. Our unique solutions enable businesses, educational institutions and municipalities of all sizes to solve everyday problems in a smarter and more cost-effective way while reducing their impact on the environment. For more information, please visit www.biohitech.com.

Company Contact:
BioHiTech Global, Inc.
Richard Galterio, Executive Vice President
Direct: 845.367.0603
[email protected]
www.biohitech.com

Investors: 
[email protected]

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/biohitech-global-reschedules-third-quarter-2020-financial-results-and-corporate-update-to-thursday-november-19-2020-301174005.html

SOURCE BioHiTech Global, Inc.

A. M. Castle & Co. Reports Third Quarter Results, Announces Agreement in Principle for New Term Loan Facility, and Extension of and Expanded Capital Access Under Existing ABL Credit Facility

Generated cash flow from operations of $3.9 million in the quar
ter and aggressively reduced costs in face of challenging end-markets

OAK BROOK, Ill., Nov. 16, 2020 (GLOBE NEWSWIRE) — A. M. Castle & Co. (OTCQX: CTAM) (the “Company” or “Castle”), a global distributor of specialty metal and supply chain solutions, today reported its third quarter 2020 financial results. The Company also announced today that it has reached an agreement in principle with certain of its stockholders to provide a new $8.0 million term loan, subordinated only to the “A” tranche of the Company’s existing revolving credit facility. Additionally, as part of this agreement in principle, the Company and its first lien lender, PNC Bank, National Association (“PNC”) agreed to extend the maturity of the Company’s existing revolving credit facility to February 28, 2023, and to amend certain aspects of the facility to provide expanded access to approximately $3.8 million of capital generated by the Company’s recent cash flow improvements. The agreement in principle is subject to customary conditions to closing, including execution of acceptable documentation and final approval, which the Company expects to complete within the next 30 days.


Third Quarter 2020 Financial Results Summary:

  • Generated net sales of $79.5 million, a 6.1% decrease compared to $84.7 million in the previous quarter and a 41.6% decrease compared to $136.1 million in the third quarter of 2019.
  • Reported an operating loss of $10.6 million, an increase in operating loss of $6.1 million compared to $4.5 million in the previous quarter and an increase in operating loss of $6.8 million compared to the same quarter last year.
  • Reported a net loss of $14.7 million, which included $5.1 million of interest expense, of which $4.1 million was non-cash, compared to a net loss of $12.2 million in the third quarter of 2019, which included $10.2 million of interest expense, of which $8.4 million was non-cash. Included in the reported net loss in the third quarter of 2020 was a foreign currency gain on intercompany loan of $0.2 million, compared to a foreign currency loss on intercompany loan of $0.5 million in the third quarter of 2019.
  • Reported adjusted net loss of $8.0 million, compared to an adjusted net loss of $3.2 million in the third quarter of the prior year.
  • Reported EBITDA of negative $8.3 million and adjusted EBITDA of negative $4.6 million in the third quarter of 2020, compared to EBITDA of negative $1.0 million and adjusted EBITDA of $1.4 million in the third quarter of 2019.
  • Cash flow provided by operations was $19.8 million during the first nine months of 2020, compared to cash flow provided by operations of $4.6 million during the first nine months of 2019.
  • Maintained gross material margin of 26.3% compared to 28.1% in the second quarter of 2020 and 25.3% in the third quarter of the prior year, which excluded a non-cash inventory charge of $1.3 million.

President and CEO, Marec Edgar commented, “From an operational perspective, we believe the third quarter was the bottom of the pandemic impacts in our volume and revenue performance. In fact, in both our industrial and aerospace end-markets we have begun to see recovery in billings and, more promisingly, in forward bookings for the coming months. That said, these improvements remain cautious and measured and we expect that returning to pre-pandemic levels will be a long, slow process. Since the pandemic began, we have responded to the rapid downturn by pulling together and implementing difficult but necessary productivity improvements and expense reductions, which have lowered our cash operating expenses by 22.7% compared to the third quarter of last year. We implemented additional aggressive steps late in the third quarter to further reduce our operating costs due to the more prolonged recovery trajectory we now anticipate. While these additional projected savings will not be fully realized until later in the fourth quarter, we believe that they have positioned Castle to be a stronger, more efficient company as our industry recovers from the impacts of the pandemic.

Mr. Edgar continued, “To that end, we appreciate the significant expression of support from our shareholders and PNC evidenced by this new term loan and the extension and expansion of our existing revolving credit facility. Access to this additional capital will enable us to more quickly rebound from the pandemic by providing us the opportunity to make additional investments in inventory, our facilities, and our people, all of which will ultimately enhance our ability to serve our customers.”

Executive Vice President of Finance and Administration Pat Anderson commented, “We are pleased to have generated cash flow from operations of $3.9 million during the quarter through disciplined expense and working capital management despite the continued disruption to the market and the substantial challenges that continue to impact our order and inventory lead times. We reacted timely and decisively to adjust our working capital and operating expenses to align our business with the unfavorable economic conditions caused by the COVID-19 pandemic, and have implemented additional steps to further rationalize our cost structure, resulting in the recognition of $0.7 million in severance costs during the quarter. Our aggressive reaction to the market downturn has resulted in our adjusted EBITDA being approximately break-even year-to-date, excluding foreign exchange impacts.”

Mr. Anderson added, “Throughout this year we have made strategic decisions to reduce operating expenses. We expect these cost reductions, which we estimate to be at least $15 million on an annualized basis, to generate increased profitability leverage as markets recover. Additionally, we have continued to use our operating cash generation to reduce our working capital debt, both in the third quarter and after, which remains one of our primary goals following the significant long-term debt reduction we achieved through our exchange offer earlier this year. We believe coupling this enhanced profitability leverage and improved balance sheet will position us well to take advantage of the eventual recovery in our end markets.”

Mr. Edgar concluded, “Though there are some signs of stabilization in our end markets, we expect revenue and volume to remain suppressed compared to historical levels in the near to medium-term as the ultimate duration and severity of the dislocation caused by COVID-19, and the timing and scope of any economic recovery thereafter, remains uncertain. Although the outlook remains challenging and volatile, we believe we are positioned to maintain positive operational performance by executing our business strategy focused on highly accretive sales, particularly those including our expanding value-added service offerings, and maintaining liquidity through expense control and enhanced execution in the management of our working capital. We remain confident that this strategy will allow us to not only survive the challenge presented by this pandemic, but thrive once we emerge from it.”

About A. M. Castle & Co.

Founded in 1890, A. M. Castle & Co. is a global distributor of specialty metal and supply chain services, principally serving the producer durable equipment, commercial aircraft, heavy equipment, industrial goods, and construction equipment sectors of the global economy. Its customer base includes many Fortune 500 companies as well as thousands of medium and smaller-sized firms spread across a variety of industries. It specializes in the distribution of alloy and stainless steels; nickel alloys; aluminum and carbon. Together, Castle and its affiliated companies operate out of 19 metals service centers located throughout North America, Europe and Asia. Its common stock is traded on the OTCQX® Best Market under the ticker symbol “CTAM”.

Non-GAAP Financial Measures

This release and the financial information included in this release include non-GAAP financial measures. The non-GAAP financial information should be considered supplemental to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. Investors should recognize that these non-GAAP financial measures might not be comparative to similarly titled measures of other companies. However, we believe that non-GAAP reporting, giving effect to the adjustments shown in the reconciliation contained in this release and in the attached financial statements, provides meaningful information, and therefore we use it to supplement our GAAP reporting and guidance. Management often uses this information to assess and measure the performance of our business. We have chosen to provide this supplemental information to investors, analysts and other interested parties to enable them to perform additional analysis of operating results, to illustrate the results of operations giving effect to the non-GAAP adjustments shown in the reconciliations and to assist with period-over-period comparisons of such operations. The exclusion of the charges indicated herein from the non-GAAP financial measures presented does not indicate an expectation by the Company that similar charges will not be incurred in subsequent periods.

In addition, the Company believes that the use and presentation of EBITDA, which is defined by the Company as loss before provision for income taxes plus depreciation and amortization, and interest expense, is widely used by the investment community for evaluation purposes and provides investors, analysts and other interested parties with additional information in analyzing the Company’s operating results. EBITDA, adjusted non-GAAP net loss and adjusted EBITDA are presented as the Company believes the information is important to provide investors, analysts and other interested parties additional information about the Company’s financial performance. Management uses EBITDA, adjusted non-GAAP net loss and adjusted EBITDA to evaluate the performance of the business.

Cautionary Statement on Risks Associated with Forward Looking Statements

Information provided and statements contained in this release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements only speak as of the date of this release and the Company assumes no obligation to update the information included in this release. Such forward-looking statements reflect our expectations, estimates or projections concerning our possible or assumed future results of operations, including, but not limited to, descriptions of our business strategy, and the benefits we expect to achieve from our working capital management initiative. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “predict,” “plan,” “should,” or similar expressions. These statements are not guarantees of performance or results, and they involve risks, uncertainties, and assumptions. Although we believe that these forward-looking statements are based on reasonable assumptions, there are many factors that could affect our actual financial results or results of operations and could cause actual results to differ materially from those in the forward-looking statements. These factors include the impact of volatility of metals prices, the cyclical and seasonal aspects of our business, our ability to effectively manage inventory levels, the impact of our substantial level of indebtedness, the impact of the novel Coronavirus (COVID-19) pandemic on our financial results and business, as well as those risk factors identified in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2019, Part II Item 1A of our quarterly report on Form 10-Q for the quarter ended March 31, 2020, Part II Item 1A of quarterly report on Form 10-Q for the quarter ended June 30, 2020, and Part II Item 1A of quarterly report on Form 10-Q for the quarter ended September 30, 2020, which will be subsequently filed with the Securities and Exchange Commission. All future written and oral forward-looking statements by us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Except as required by the federal securities laws, we do not have any obligations or intention to release publicly any revisions to any forward-looking statements to reflect events or circumstances in the future, to reflect the occurrence of unanticipated events or for any other reason.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
  Three Months Ended   Nine Months Ended
(Dollars in thousands, except per share data) September 30,   September 30,
Unaudited 2020   2019   2020   2019
Net sales $ 79,535     $ 136,113     $ 290,857     $ 433,570  
Costs and expenses:              
Cost of materials (exclusive of depreciation) 58,610     103,019     211,806     323,918  
Warehouse, processing and delivery expense 13,394     18,759     45,584     59,577  
Sales, general and administrative expense 13,515     16,048     41,815     49,027  
Depreciation expense 1,921     2,055     6,035     6,306  
Impairment of goodwill 2,676         2,676      
Total costs and expenses 90,116     139,881     307,916     438,828  
Operating loss (10,581 )   (3,768 )   (17,059 )   (5,258 )
Interest expense, net 5,077     10,204     20,146     29,503  
Unrealized gain on embedded debt conversion option         (2,010 )    
Other (income) expense, net (342 )   (697 )   (2,194 )   (4,779 )
Loss before income taxes (15,316 )   (13,275 )   (33,001 )   (29,982 )
Income tax benefit (572 )   (1,079 )   (3,163 )   (1,479 )
Net loss $ (14,744 )   $ (12,196 )   $ (29,838 )   $ (28,503 )

Reconciliation of Reported Net Loss to EBITDA and Adjusted EBITDA:
  Three Months Ended   Nine Months Ended
(Dollars in thousands) September 30,   September 30,
Unaudited 2020   2019   2020   2019
Net loss, as reported $ (14,744 )   $ (12,196 )   $ (29,838 )   $ (28,503 )
Depreciation expense 1,921     2,055     6,035     6,306  
Interest expense, net 5,077     10,204     20,146     29,503  
Income tax benefit (572 )   (1,079 )   (3,163 )   (1,479 )
EBITDA (8,318 )   (1,016 )   (6,820 )   5,827  
Non-GAAP adjustments (a) 3,690     2,367     4,923     2,626  
Adjusted EBITDA $ (4,628 )   $ 1,351      $ (1,897 )   $ 8,453   
               
(a) Refer to “Reconciliation of Reported Net Loss to Adjusted Non-GAAP Net Loss” table for additional details on these amounts.

Reconciliation of Reported Net Loss to Adjusted Non-GAAP Net Loss:              
  Three Months Ended   Nine Months Ended
(Dollars in
thousands)
September 30,   September 30,
Unaudited 2020   2019   2020   2019
Net loss, as reported $ (14,744 )   $ (12,196 )   $ (29,838 )   $ (28,503 )
Non-GAAP adjustments:              
Noncash compensation expense 199     524     778     1,715  
Foreign exchange (gain) loss on intercompany loan (215 )   506     692     (426 )
Noncash impairment of goodwill(a) 2,676         2,676      
Noncash write-off on inventory(b)     1,277         1,277  
Noncash loss on disposal of equipment(b)     60         60  
Unrealized gain on embedded debt conversion option         (2,010 )    
Common stock registration fees 294         294      
Employee severance charges 736         1,117      
Debt restructuring expenses         1,376      
Non-GAAP adjustments to arrive at Adjusted EBITDA 3,690     2,367     4,923     2,626  
Non-cash interest expense(c) 3,054     7,139     13,484     20,321  
Total non-GAAP adjustments 6,744     9,506     18,407     22,947  
Tax effect of adjustments     (468 )       (468 )
Adjusted non-GAAP net loss $ (8,000 )   $ (3,158 )   $ (11,431 )   $ (6,024 )
               
(a) Due to the ongoing unfavorable impacts of the COVID-19 pandemic, which represented a triggering event in the third quarter of 2020, the Company performed an assessment of its goodwill as of September 30, 2020. As a result of the goodwill impairment assessment, the Company recorded a non-cash impairment charge of $2.7 million during the third quarter of fiscal 2020.
(b) Amounts relates to the nonrecurring noncash disposal of equipment and nonrecurring noncash write-down of inventory in conjunction with the Company’s decision to exit a portion of its carbon flat-roll business in one of its Mexican operations.
(c) Non-cash interest expense for the three months ended September 30, 2020 and September 30, 2019 includes interest paid in kind of $2,112 and $4,022, respectively, and amortization of debt discount of $942 and $2,829, respectively. Non-cash interest expense for the nine months ended September 30, 2020 and September 30, 2019 includes interest paid in kind of $8,277 and $11,810, respectively, and amortization of debt discount of $5,207 and $8,511, respectively.

CONDENSED CONSOLIDATED BALANCE SHEETS  
(Dollars in thousands, except par value data) As of
Unaudited September 30, 2020   December 31, 2019
ASSETS      
Current assets:      
Cash and cash equivalents $ 24,230     $ 6,433  
Accounts receivable 46,768     74,697  
Inventories 140,085     144,411  
Prepaid expenses and other current assets 9,717     9,668  
Income tax receivable 2,486     1,995  
Total current assets 223,286     237,204  
Goodwill and intangible assets 5,500     8,176  
Prepaid pension cost 7,504     5,758  
Deferred income taxes 1,497     1,534  
Operating right-of-use assets 29,943     29,423  
Other noncurrent assets 550     792  
Property, plant and equipment:      
Land 5,578     5,579  
Buildings 20,928     20,950  
Machinery and equipment 41,562     41,054  
Property, plant and equipment, at cost 68,068     67,583  
Accumulated depreciation (24,115 )   (20,144 )
Property, plant and equipment, net 43,953     47,439  
Total assets $ 312,233     $ 330,326  
LIABILITIES AND STOCKHOLDERS’ DEFICIT      
Current liabilities:      
Accounts payable $ 40,589     $ 41,745  
Accrued and other current liabilities 10,785     11,188  
Operating lease liabilities 6,508     6,537  
Income tax payable 542     573  
Short-term borrowings 1,980     2,888  
Current portion of finance leases 663     596  
Current portion of long-term debt 2,000      
Total current liabilities 63,067     63,527  
Long-term debt, less current portion 213,253     263,523  
Deferred income taxes 1,543     3,775  
Finance leases, less current portion 7,893     8,208  
Other noncurrent liabilities 3,621     2,894  
Pension and postretirement benefit obligations 6,554     6,709  
Noncurrent operating lease liabilities 23,563     22,760  
Commitments and contingencies      
Stockholders’ equity (deficit):      
Common stock, $0.01 par value—400,000 Class A shares authorized with 74,079
shares issued and — shares outstanding at September 30, 2020, and 3,818 shares
issued and 3,650 shares outstanding at December 31, 2019
741     38  
Additional paid-in capital 123,958     61,461  
Accumulated deficit (118,579 )   (88,741 )
Accumulated other comprehensive loss (12,927 )   (13,374 )
Treasury stock, at cost — 168 shares at September 30, 2020 and 168 shares at December 31, 2019 (454 )   (454 )
Total stockholders’ equity (deficit) (7,261 )   (41,070 )
Total liabilities and stockholders’ deficit $ 312,233     $ 330,326  

CONSOLIDATED STATEMENTS OF CASH FLOWS
  Nine Months Ended
(Dollars in thousands) September 30,
Unaudited 2020   2019
Operating activities:      
Net loss $ (29,838 )   $ (28,503 )
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:      
Depreciation 6,035     6,306  
Amortization of deferred financing costs and debt discount 5,207     8,511  
Loss on sale of property, plant & equipment 101     210  
Unrealized foreign currency loss (gain) 682     (223 )
Unrealized gain on embedded debt conversion option (2,010 )    
Noncash interest paid in kind 8,277     11,810  
Noncash rent expense 290     204  
Noncash compensation expense 778     1,715  
Noncash impairment of goodwill 2,676      
Deferred income taxes (2,319 )   (2,016 )
Changes in assets and liabilities:      
Accounts receivable 27,926     (8,356 )
Inventories 4,679     10,029  
Prepaid expenses and other current assets (39 )   5,873  
Other noncurrent assets 911     (134 )
Prepaid pension costs (1,671 )   (566 )
Accounts payable (1,460 )   5,093  
Income tax payable and receivable (512 )   (1,805 )
Accrued and other current liabilities (448 )   (3,451 )
Pension and postretirement benefit obligations and other noncurrent liabilities 572     (111 )
Net cash provided by operating activities 19,837     4,586  
Investing activities:      
Capital expenditures (2,426 )   (3,530 )
Proceeds from sale of property, plant and equipment 78     442  
Net cash used in investing activities (2,348 )   (3,088 )
Financing activities:      
Proceeds from long-term debt including credit facilities 19,673     3,500  
Repayments of long-term debt including credit facilities (15,655 )   (4,488 )
Repayments of (proceeds from) short-term borrowings, net (931 )   (1,238 )
Principal paid on finance leases (243 )   (454 )
Payments of debt restructuring costs (2,752 )    
Net cash provided by (used in) financing activities 92     (2,680 )
Effect of exchange rate changes on cash and cash equivalents 216     13  
Net change in cash and cash equivalents 17,797     (1,169 )
Cash and cash equivalents—beginning of year 6,433     8,668  
Cash and cash equivalents—end of period $ 24,230     $ 7,499  

LONG-TERM DEBT      
(Dollars in thousands) As of
  September 30, 2020   December 31, 2019
       
Floating rate Revolving A Credit Facility due February 28, 2022 $ 89,246     $ 102,000  
12.00% Revolving B Credit Facility due February 28, 2022(a) 28,216     25,788  
3.00% / 5.00% Convertible Senior Secured PIK Toggle Notes
due August 31, 2024(b)
97,568      
5.00% / 7.00% Convertible Senior Secured PIK Toggle Notes
due August 31, 2022(c)
3,890     193,660  
1.00% Paycheck Protection Program Term Note due April 28, 2022 10,000      
France Term Loan 7,020      
Total principal balance of long-term debt 235,940     321,448  
Less: unvested restricted 3.00% / 5.00% Convertible Senior Secured PIK Toggle Notes due August 31, 2024(d) (109 )    
Less: unvested restricted 5.00% / 7.00% Convertible Senior Secured PIK Toggle Notes due August 31, 2022(d)     (323 )
Less: unamortized discount (20,389 )   (57,313 )
Less: unamortized debt issuance costs (189 )   (289 )
Total long-term debt 215,253     263,523  
Less: current portion of long-term debt 2,000      
Total long-term portion $ 213,253     $ 263,523  
       
(a) Included in balance is interest paid in kind of $6,716 as of September 30, 2020 and $4,288 as of December 31, 2019.
(b) Included in balance is interest paid in kind of $2,434 as of September 30, 2020.  
(c) Included in balance is interest paid in kind of $198 as of September 30, 2020 and $28,991 as of December 31, 2019.
(d) Represents the unvested portion of restricted 3.00% / 5.00% Convertible Senior Secured PIK Toggle Notes due August 31, 2024 issued to certain members of management and the unvested portion of restricted 5.00% / 7.00% Convertible Senior Secured PIK Toggle Notes due August 31, 2022 issued to certain members of management.

For Further Information:

Ed Quinn
+1 (847) 455-7111
Email: [email protected] 



Kodiak Sciences Announces Proposed Offering of Common Stock

PR Newswire

PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has commenced an underwritten public offering of $400,000,000 of shares of its common stock. In connection with the proposed offering, Kodiak Sciences expects to grant the underwriters a 30-day option to purchase up to an additional $60,000,000 of shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the proposed offering will be sold by Kodiak Sciences. The proposed offering is subject to market and other conditions, and there can be no assurances as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the proposed offering.  Truist Securities is acting as lead manager for the proposed offering.

The shares described above are being offered by Kodiak Sciences pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was previously filed by Kodiak Sciences with the Securities and Exchange Commission (the “SEC”) and that became automatically effective on November 16, 2020. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering, when available, may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at 866-803-9204 or by email at [email protected]; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014 or by email at [email protected]; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at (877) 821-7388, or by email at [email protected]; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Kodiak Sciences Inc.

Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Kodiak’s lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, a leading cause of blindness in elderly patients, and diabetic eye diseases, a leading cause of blindness in working-age patients.

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the completion, timing and size of the proposed public offering. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Kodiak Sciences’ most recent Form 10-Q, as well as in the preliminary prospectus supplement related to the proposed public offering to be filed with the SEC. These forward-looking statements speak only as of the date hereof and Kodiak Sciences undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

Cision View original content:http://www.prnewswire.com/news-releases/kodiak-sciences-announces-proposed-offering-of-common-stock-301173937.html

SOURCE Kodiak Sciences Inc.

Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Wednesday, December 2, 2020 at 7:30 a.m. ET. Management will be available December 1st and 2nd throughout the day for virtual one-on-one meetings.

A live audio webcast of the fireside chat may be accessed through the Events page under the Investors section of Aclaris’ website, www.aclaristx.com. An archived version of the webcast will be available for 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.

Aclaris Contact

[email protected]



WidePoint Reports Third Quarter 2020 Financial Results

FAIRFAX, Va., Nov. 16, 2020 (GLOBE NEWSWIRE) —  WidePoint Corporation (NYSE American: WYY), the leading provider of Trusted Mobility Management (TM2) specializing in Telecommunications Lifecycle Management, Identity Management (IdM) and Digital Billing & Analytics solutions, today reported results for the third quarter September 30, 2020.

Third
Quarter
2020
and Recent Operational Highlights:

  • Secured more than $11 million in contract wins, exercised option periods, and contract extensions during the third quarter of 2020, approximately $10 million of which is comprised of new business and new extensions
  • Successfully onboarded Virginia Alcoholic Beverage Control Authority (Virginia ABC) after being awarded a new contract for TEM services
  • Number of U.S. Department of Defense digital certificates issued increased 14% sequentially from the second quarter of 2020 and 15% year-over-year from the third quarter of 2019, leading to an increase in high margin Identity Management revenue
  • Responded to the request for proposal and provided oral presentation to the U.S. Department of Homeland Security regarding the Cellular Wireless Managed Services (CWMS) II contract re-compete
  • Effectuated 1-for-10 reverse stock split on November 6, 2020 to better position the Company for long-term success

Third
Quarter
2020
Financial Highlights (
results compared to the same year-ago period)
:

  • Revenues increased 94% to $57.5 million
  • Managed Services revenue increased 38% to $12.5 million
  • Gross profit increased 30% to $5.6 million
  • Net income totaled $1.1 million
  • EBITDA, a non-GAAP financial measure, increased 102% to $1.6 million
  • Adjusted EBITDA, a non-GAAP financial measure, increased 82% to $1.7 million

Nine
Month
2020
Financial Highlights (results compared to the same year-ago period):

  • Revenues increased 106% to $152.0 million
  • Managed Services revenue increased 37% to $33.8 million
  • Gross profit increased 24% to $15.6 million
  • Net income totaled $2.0 million
  • EBITDA, a non-GAAP financial measure, increased 84% to $3.8 million
  • Adjusted EBITDA, a non-GAAP financial measure, increased 69% to $4.4 million

Third
Quarter
2020
Financial Summary
     
       
       
(in millions, except per share amounts) September 30, 2020   September 30, 2019
  (Unaudited)
Revenues $ 57.5     $ 29.6  
Gross Profit $ 5.6     $ 4.3  
Gross Profit Margin   9.8 %     14.6 %
Operating Expenses $ 4.5     $ 4.0  
Income (Loss) from Operations $ 1.1     $ 0.3  
Net Income (Loss) $ 1.1     $ 0.2  
Basic and Diluted Earnings per Share (EPS) $ 0.13     $ 0.02  
EBITDA $ 1.6     $ 0.8  
       
       
       
Nine
Month
2020
Financial Summary 
     
       
       
(in millions, except per share amounts) September 30, 2020   September 30, 2019
  (Unaudited)
Revenues $ 152.0     $ 73.6  
Gross Profit $ 15.6     $ 12.6  
Gross Profit Margin   10.3 %     17.1 %
Operating Expenses $ 13.1     $ 12.0  
Income from Operations $ 2.5     $ 0.6  
Net Income $ 2.0     $ 0.3  
Basic and Diluted Earnings per Share (EPS) $ 0.24     $ 0.03  
EBITDA $ 3.8     $ 2.0  
       


The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under the “Safe Harbor Statement” below.

Financial Outlook

For the fiscal year ending December 31, 2020, the Company is reiterating its revenue guidance of $185 million to $195 million, which at the midpoint of the range, would represent 87% growth year-over-year. The Company is also reiterating the EBITDA guidance it updated on October 26, 2020 of $4.7 million to $4.9 million, which at the midpoint, is 50% above the Company’s previously issued EBITDA guidance and represents a 69% year-over-year increase compared to fiscal 2019. For fiscal 2020, the Company also anticipates adjusted EBITDA, which excludes stock-based compensation expense, to range between $5.5 million to $5.7 million, which, at the midpoint, represents a 57% year-over-year increase compared to fiscal 2019. The EBITDA forecast takes into consideration the Company’s planned strategic investments in sales and marketing and product development. The Company’s financial outlook is based on current expectations.

Management Commentary

“Thanks to the work of our dedicated personnel and the flexibility we built into our organization, we continued to build on the momentum established in the first half of the year and produced record financial results for the third quarter of 2020,” said WidePoint’s CEO, Jin Kang. “For the third quarter, our total revenues increased to $57.5 million, largely driven by our increased work on the U.S. Census 2020 as well as expansions with other federal government customers, and perhaps more importantly, our high margin managed services revenues increased 38% year-over-year. That increase helped drive $1.1 million in net income for the third quarter, which is almost five times greater than our net income in all of fiscal 2019, and our adjusted EBITDA for the quarter increased 82% to $1.7 million. We also strengthened our balance sheet by increasing our cash position by $3.9 million sequentially to $11.4 million.

“The financial success of the quarter is a clear indication of the value WidePoint can generate because of our excellent staff, our flexible organizational structure, and the market’s growing demand for our products that function as a solution for many of the problems faced by large government and commercial enterprises in today’s environment. With 2020 lining up to be a banner year for WidePoint, we believe our company has never been better positioned than it is today, and we look forward to capitalizing on this momentum as we close out the year and move into 2021.”

Conference Call

WidePoint management will hold a conference call today (November 16, 2020) at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) to discuss these results.

WidePoint’s President and CEO Jin Kang, Executive Vice President and Chief Sales and Marketing Officer Jason Holloway, and Executive Vice President and CFO Kellie Kim will host the conference call, followed by a question and answer period.

U.S. dial-in number: 844-407-9500
International number: 862-298-0850

Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Gateway Investor Relations at 949-574-3860.

The conference call will be broadcast live and available for replay here and via the investor relations section of the Company’s website.

A replay of the conference call will be available after 7:30 p.m. Eastern time on the same day through November 30, 2020.

Toll-free replay number: 877-481-4010
International replay number: 919-882-2331
Replay ID: 38150

About WidePoint

WidePoint Corporation (NYSE American: WYY) is a leading provider of trusted mobility management (TM2) solutions, including telecom management, mobile management, identity management, and digital billing and analytics. For more information, visit widepoint.com.

Non-GAAP Financial Measures

WidePoint uses a variety of operational and financial metrics, including non-GAAP financial measures such as EBITDA, to enable it to analyze its performance and financial condition. The presentation of non-GAAP financial information should not be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. A reconciliation of GAAP Net income to EBITDA is included on the schedules attached hereto.   

                       
        THREE MONTHS ENDED   NINE MONTHS ENDED  
        SEPTEMBER 30,   SEPTEMBER 30,  
          2020       2019       2020       2019    
        (Unaudited)   (Unaudited)  
NET INCOME $ 1,067,000     $ 183,700     $ 2,039,500     $ 260,100    
Adjustments to reconcile net (loss) income to EBITDA:                
  Depreciation and amortization   415,700       479,300       1,247,100       1,429,100    
  Amortization of deferred financing costs         1,300       1,700       3,800    
  Income tax provision (benefit)   12,500       32,300       242,800       126,800    
  Interest income   (100 )     (100 )     (3,100 )     (4,800 )  
  Interest expense   69,600       76,800       226,200       227,200    
                       
EBITDA   $ 1,564,700     $ 773,300     $ 3,754,200     $ 2,042,200    
Other adjustments to reconcile net (loss) income to Adjusted EBITDA:                
  (Recovery) Provision for doubtful accounts       12,300       600       23,500    
  Gain on sale of assets held for sale                        
  Loss on disposal of leasehold improvements                        
  Lease account impact on EBITDA                      
  Stock-based compensation expense   160,000       163,400       650,900       536,800    
                       
Adjusted EBITDA $ 1,724,700     $ 949,000     $ 4,405,700     $ 2,602,500    
                       

 


Safe Harbor Statement

The information contained in any materials that may be accessed above was, to the best of WidePoint Corporations’ knowledge, timely and accurate as of the date and/or dates indicated in such materials. However, the passage of time can render information stale, and you should not rely on the continued accuracy of any such materials. WidePoint Corporation has no responsibility to update any information contained in any such materials. In addition, you should refer to periodic reports filed by WidePoint Corporation with the Securities and Exchange Commission for information regarding the risks and uncertainties to which forward-looking statements made in such materials are subject. Such risks and uncertainties may cause WidePoint Corporation’s actual results to differ materially from those described in the forward-looking statements.

Investor Relations:

Gateway Investor Relations
Matt Glover or Charlie Schumacher
949-574-3860
[email protected]



WIDEPOINT CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

         
  SEPTEMBER 30,   DECEMBER 31,  
    2020       2019    
  (Unaudited)  
ASSETS  
CURRENT ASSETS        
Cash and cash equivalents $ 11,372,902     $ 6,879,627    
Accounts receivable, net of allowance for doubtful accounts        
of $119,248 and $126,235 in 2020 and 2019, respectively   31,469,534       14,580,928    
Unbilled accounts receivable   15,041,634       13,976,958    
Other current assets   1,099,773       1,094,847    
         
Total current assets   58,983,843       36,532,360    
         
NONCURRENT ASSETS        
Property and equipment, net   619,773       681,575    
Operating lease right of use asset, net   6,299,131       5,932,769    
Intangibles, net   2,076,320       2,450,770    
Goodwill   18,555,578       18,555,578    
Other long-term assets   874,906       140,403    
         
Total assets $ 87,409,551     $ 64,293,455    
         
LIABILITIES AND STOCKHOLDERS’ EQUITY  
         
CURRENT LIABILITIES        
Accounts payable $ 30,954,163     $ 13,581,822    
Accrued expenses   17,348,047       14,947,981    
Deferred revenue   2,270,783       2,265,067    
Current portion of operating lease liabilities   580,483       599,619    
Current portion of other term obligations         133,777    
         
Total current liabilities   51,153,476       31,528,266    
         
NONCURRENT LIABILITIES        
Operating lease liabilities, net of current portion   6,097,949       5,593,649    
Deferred revenue, net of current portion   382,814       363,560    
Deferred tax liability   2,100,446       1,868,562    
         
Total liabilities   59,734,685       39,354,037    
         
Commitments and contingencies            
         
STOCKHOLDERS’ EQUITY        
Preferred stock, $0.001 par value; 10,000,000 shares        
authorized; 2,045,714 shares issued and none outstanding            
Common stock, $0.001 par value; 30,000,000 shares        
  authorized; 8,458,734 and 8,386,145 shares        
issued and outstanding, respectively   84,587       83,861    
Additional paid-in capital   95,919,199       95,279,114    
Accumulated other comprehensive loss   (187,435 )     (242,594 )  
Accumulated deficit   (68,141,485 )     (70,180,963 )  
         
Total stockholders’ equity   27,674,866       24,939,418    
         
Total liabilities and stockholders’ equity $ 87,409,551     $ 64,293,455    
         




WIDEPOINT CORPORATION AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


                       
        THREE MONTHS ENDED   NINE MONTHS ENDED  
        SEPTEMBER 30,   SEPTEMBER 30,  
          2020       2019       2020       2019    
        (Unaudited)   (Unaudited)  
REVENUES $ 57,506,561     $ 29,616,940     $ 151,955,707     $ 73,626,995    
COST OF REVENUES (including amortization and depreciation of                
  $130,559, $233,033, $432,327, and $698,192, respectively)   51,888,205       25,302,919       136,314,439       61,002,387    
                       
GROSS PROFIT   5,618,356       4,314,021       15,641,268       12,624,608    
                       
OPERATING EXPENSES                
  Sales and marketing   500,015       406,683       1,431,930       1,215,556    
  General and administrative expenses (including share-based                
    compensation of $160,056, $163,451, $650,924 and $536,828, respectively)     3,684,344       3,372,269       10,887,952       10,070,383    
  Depreciation and amortization   285,181       246,293       814,813       730,905    
                       
    Total operating expenses      4,469,540       4,025,245       13,134,695       12,016,844    
                       
INCOME FROM OPERATIONS   1,148,816       288,776       2,506,573       607,764    
                       
OTHER (EXPENSE) INCOME                
  Interest income   94       40       3,119       4,761    
  Interest expense   (69,582 )     (78,066 )     (227,889 )     (230,983 )  
  Other income   118       5,324       458       5,324    
                       
    Total other expense      (69,370 )     (72,702 )     (224,312 )     (220,898 )  
                       
INCOME BEFORE INCOME TAX PROVISION   1,079,446       216,074       2,282,261       386,866    
INCOME TAX PROVISION   12,483       32,364       242,783       126,816    
                       
NET INCOME $ 1,066,963     $ 183,710     $ 2,039,478     $ 260,050    
                       
BASIC EARNINGS PER SHARE $ 0.13     $ 0.02     $ 0.24     $ 0.03    
                       
BASIC WEIGHTED-AVERAGE SHARES OUTSTANDING   8,450,843       8,423,435       8,409,114       8,401,405    
                       
DILUTED EARNINGS PER SHARE $ 0.13     $ 0.02     $ 0.24     $ 0.03    
                       
DILUTED WEIGHTED-AVERAGE SHARES OUTSTANDING   8,527,309       8,427,183       8,463,561       8,405,152    
                       
        THREE MONTHS ENDED   NINE MONTHS ENDED  
        SEPTEMBER 30,   SEPTEMBER 30,  
          2020       2019       2020       2019    
        (Unaudited)   (Unaudited)  
NET INCOME $ 1,067,000     $ 183,700     $ 2,039,500     $ 260,100    
Adjustments to reconcile net (loss) income to EBITDA:                
  Depreciation and amortization   415,700       479,300       1,247,100       1,429,100    
  Amortization of deferred financing costs         1,300       1,700       3,800    
  Income tax provision (benefit)   12,500       32,300       242,800       126,800    
  Interest income   (100 )     (100 )     (3,100 )     (4,800 )  
  Interest expense   69,600       76,800       226,200       227,200    
                       
EBITDA   $ 1,564,700     $ 773,300     $ 3,754,200     $ 2,042,200    
Other adjustments to reconcile net (loss) income to Adjusted EBITDA:                
  (Recovery) Provision for doubtful accounts       12,300       600       23,500    
  Gain on sale of assets held for sale                        
  Loss on disposal of leasehold improvements                        
  Severance and exit costs                        
  Lease account impact on EBITDA                      
  Stock-based compensation expense   160,000       163,400       650,900       536,800    
                       
Adjusted EBITDA $ 1,724,700     $ 949,000     $ 4,405,700     $ 2,602,500